Follow
Andreas Kateifides, MD, PhD
Andreas Kateifides, MD, PhD
Alexion Pharmaceuticals
Verified email at bu.edu
Title
Cited by
Cited by
Year
Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels
CL Haase, R Frikke‐Schmidt, BG Nordestgaard, AK Kateifides, ...
Journal of internal medicine 270 (2), 136-146, 2011
482011
ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT [S]
A Duka, P Fotakis, D Georgiadou, A Kateifides, K Tzavlaki, ...
Journal of lipid research 54 (1), 107-115, 2013
472013
Apolipoprotein AI exerts bactericidal activity against Yersinia enterocolitica serotype O: 3
M Biedzka-Sarek, J Metso, A Kateifides, T Meri, TS Jokiranta, A Muszyński, ...
Journal of Biological Chemistry 286 (44), 38211-38219, 2011
472011
Carboxyl terminus of apolipoprotein AI (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells
PM Ohnsorg, L Rohrer, D Perisa, A Kateifides, A Chroni, D Kardassis, ...
Journal of biological chemistry 286 (10), 7744-7754, 2011
362011
Significance of the hydrophobic residues 225–230 of apoA-I for the biogenesis of HDL1 [S]
P Fotakis, I Tiniakou, AK Kateifides, C Gkolfinopoulou, A Chroni, ...
Journal of lipid research 54 (12), 3293-3302, 2013
172013
Role of the hydrophobic and charged residues in the 218–226 region of apoA-I in the biogenesis of HDL1 [S]
P Fotakis, AK Kateifides, C Gkolfinopoulou, D Georgiadou, M Beck, ...
Journal of lipid research 54 (12), 3281-3292, 2013
172013
Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans
G Samonis, S Maraki, K Leventakos, AM Spanaki, A Kateifidis, ...
Medical mycology 44 (3), 233-235, 2006
172006
Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL [S]
AK Kateifides, IN Gorshkova, A Duka, A Chroni, D Kardassis, VI Zannis
Journal of Lipid Research 52 (7), 1363-1372, 2011
142011
Pleiotropic functions of HDL lead to protection from atherosclerosis and other diseases
V Zannis, A Kateifides, P Fotakis, E Zanni, D Kardassis
Dyslipidemia-From Prevention to Treatment, 173-96, 2012
122012
WCN23-0140 A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF RAVULIZUMAB IN PATIENTS WITH IMMUNOGLOBULIN A (IgA) NEPHROPATHY OR PROLIFERATIVE LUPUS NEPHRITIS (LN)
A Kateifides, K Garlo, K Rice, N Spoerri, N Najafian
Kidney International Reports 8 (3), S54-S55, 2023
12023
Mutation in APOA1 predicts increased risk of ischaemic heart disease and mortality without low HDL cholesterol
CL Haase, R Frikke-Schmidt, BG Nordestgaard, AK Kateifides, ...
Amyloid 17, 129, 2010
2010
119 MUTATION IN APOAI PREDICTS INCREASED RISK OF ISCHEMIC HEART DISEASE AND EARLY DEATH WITHOUT LOW HDL CHOLESTEROL
C Lundegaard, R Frikke-Schmidt, B Nordestgaard, A Kateifides, ...
Atherosclerosis (Supplements)(Component) 2 (10), e235, 2009
2009
Resequencing APOAI Identifies Common Mutation that Predicts Increased Risk of Ischemic Heart Disease and Decreased Longevity without Dyslipidemia
C Lundegaard, R Frikke-Schmidt, BG Nordestgaard, AK Kateifides, ...
Circulation 118 (suppl_18), S_955-S_955, 2008
2008
A Phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A nephropathy or proliferative lupus nephritis (LN)
A Kateifides, K Garlo, K Rice, N Spoerri, N Najafian
The system can't perform the operation now. Try again later.
Articles 1–14